Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Clinical Trials01:16

Clinical Trials

10.9K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
10.9K
Bioavailability Study Design: Healthy Subjects Versus Patients01:15

Bioavailability Study Design: Healthy Subjects Versus Patients

190
Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...
190

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Clinical and genomic predictors of sipuleucel-T outcomes in men with metastatic androgen pathway modulator resistant prostate cancer.

Research square·2026
Same author

Reply to: PCWG4: A Missed Opportunity to Make Bone-Protective Agents Mandatory for Patients With Bone Metastatic Castration-Resistant Prostate Cancer.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

Development and Validation of a Computational Histology Artificial Intelligence-Powered Biomarker in Metastatic Hormone-Sensitive Prostate Cancer on Randomized Phase III Trials.

JCO precision oncology·2026
Same author

Germline CDK12 variants in aggressive prostate cancer.

Cancer discovery·2026
Same author

Long-term follow-up from the OMNIVORE trial: response-adaptive nivolumab and ipilimumab in advanced renal cell carcinoma.

Journal for immunotherapy of cancer·2026
Same author

Casdatifan shows durable response linked to HIF-2α biology in kidney cancer.

Nature·2026

Related Experiment Video

Updated: Feb 27, 2026

Establishment and Maintenance of Patient-derived Prostate Cancer Organoids: A Detailed Experimental Protocol
09:04

Establishment and Maintenance of Patient-derived Prostate Cancer Organoids: A Detailed Experimental Protocol

Published on: November 14, 2025

529

Trial Design and Objectives for Patients With Prostate Cancer: Recommendations From the Prostate Cancer Working Group

Andrew J Armstrong1, Michael J Morris2, Wassim Abida2

  • 1Department of Medicine, Duke Cancer Institute Center for Prostate and Urologic Cancer, Duke University, Durham, NC.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|February 26, 2026
PubMed
Summary
This summary is machine-generated.

Updated criteria for advanced prostate cancer clinical trials are provided, focusing on new terminology, imaging, and patient stratification. These guidelines aim to optimize treatment benefits for a diverse patient population.

More Related Videos

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer
13:19

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

Published on: November 2, 2013

17.2K
A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance
05:19

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

930

Related Experiment Videos

Last Updated: Feb 27, 2026

Establishment and Maintenance of Patient-derived Prostate Cancer Organoids: A Detailed Experimental Protocol
09:04

Establishment and Maintenance of Patient-derived Prostate Cancer Organoids: A Detailed Experimental Protocol

Published on: November 14, 2025

529
Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer
13:19

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

Published on: November 2, 2013

17.2K
A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance
05:19

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

930

Area of Science:

  • Oncology
  • Clinical Trial Design
  • Prostate Cancer Research

Background:

  • Advanced prostate cancer research requires updated terminology and best practices for clinical trials.
  • New imaging modalities, molecular phenotyping, and therapies necessitate revised trial conduct standards.

Purpose of the Study:

  • To formulate updated criteria for advanced prostate cancer clinical trials based on emerging evidence.
  • To provide guidance on trial design, eligibility, and endpoint assessments in a biomarker context.

Main Methods:

  • Convened an international expert committee, Prostate Cancer Working Group 4 (PCWG4), from 2016-2025.
  • Formulated updated criteria using emerging evidence and clinical trial data.

Main Results:

  • Redefined disease state terminology, focusing on androgen pathway modulation and patient-centric contexts.
  • Established new recommendations for eligibility, response endpoints, imaging (including PET-defined disease), and patient-reported outcomes.
  • Emphasized the need for validated imaging and molecular criteria for risk stratification and outcome assessment.

Conclusions:

  • PCWG4 provides updated recommendations for patient and tumor characterization, therapy development, and imaging criteria.
  • Guidance is extended to earlier disease states to accommodate an evolving and heterogeneous patient population.
  • The goal is to optimize treatment benefits for all advanced prostate cancer patients.